Loading company…
YSOPIA Bioscience develops gut microbiome-based drugs for obesity and cardiometabolic diseases.
YSOPIA Bioscience researches and develops gut microbiome-based drugs for obesity and cardiometabolic diseases. Founded in 2010, it is based in Bordeaux, France, and was previously known as LNC Therapeutics. The company has reached Series A.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in